The REGISTER Study: A multicentre phase II study of risk evaluation in gastrointestinal stromal tumours (GIST) with selective therapy escalation for response including treatment with imatinib (400 - 800mg/day) followed by nilotinib (800mg/day).

Trial Profile

The REGISTER Study: A multicentre phase II study of risk evaluation in gastrointestinal stromal tumours (GIST) with selective therapy escalation for response including treatment with imatinib (400 - 800mg/day) followed by nilotinib (800mg/day).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms REGISTER
  • Most Recent Events

    • 08 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 11 May 2012 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 27 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top